Wong P N, Mak S K, Lo K Y, Tong G M, Wong A K
Department of Medicine, Kwong Wah Hospital, Hong Kong, China.
Adv Perit Dial. 1998;14:11-3.
While theoretically the vasoconstriction associated with the rise in hemoglobin (Hb) level may potentially alter peritoneal transport characteristics, the effect of recombinant human erythropoietin (rHuEPO) therapy on peritoneal transport in continuous ambulatory peritoneal dialysis (CAPD) patients remains unclear. We have therefore performed a prospective study on the short-term effect of rHuEPO on the peritoneal transport characteristics in terms of the change in corrected dialysate/plasma creatinine (D/Pcr) in the fast peritoneal equilibration test (PET). Eight consecutive CAPD patients started on rHuEPO had fast PETs performed before and 4 to 6 months after the initiation of rHuEPO therapy. Another 8 CAPD patients with stable Hb levels not receiving rHuEPO served as a control group. All patients (study and control) had been on CAPD therapy for more than 3 months upon enrollment, and none had peritonitis during the study period. Patients receiving rHuEPO showed significant increase in Hb level, while the Hb levels of those in the control group remained unchanged. Neither the study nor the control group patients showed significant change in the corrected D/Pcr value over a mean observation period of 5.25 +/- 0.89 months. While rHuEPO appears to be effective in increasing the Hb level in CAPD patients, there is no significant impact on the corrected D/Pcr in the fast PET test observed in this short-term study.
理论上，与血红蛋白（Hb）水平升高相关的血管收缩可能会改变腹膜转运特性，但重组人促红细胞生成素（rHuEPO）治疗对持续非卧床腹膜透析（CAPD）患者腹膜转运的影响仍不清楚。因此，我们进行了一项前瞻性研究，观察rHuEPO对腹膜转运特性的短期影响，通过快速腹膜平衡试验（PET）中校正后的透析液/血浆肌酐（D/Pcr）变化来评估。连续8例开始使用rHuEPO的CAPD患者在开始rHuEPO治疗前及治疗4至6个月后进行了快速PET检查。另外8例血红蛋白水平稳定且未接受rHuEPO治疗的CAPD患者作为对照组。所有患者（研究组和对照组）在入组时均已接受CAPD治疗超过3个月，且在研究期间均未发生腹膜炎。接受rHuEPO治疗的患者Hb水平显著升高，而对照组患者的Hb水平保持不变。在平均5.25±0.89个月的观察期内，研究组和对照组患者的校正D/Pcr值均未出现显著变化。虽然rHuEPO似乎能有效提高CAPD患者的Hb水平，但在这项短期研究中，未观察到其对快速PET试验中的校正D/Pcr有显著影响。
